Gallagher Neil 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Gallagher Neil
President, Head of R&D
Transactions
- Sale
Common Stock
2025-02-10$15.50/sh−4,618$71,597→ 85,095 total
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.